Date:7/30/2009

ties 137,314 10,949 ------- ------ Effect of exchange rate changes on cash and cash equivalents 1,918 14 ----- -- Net increase (decrease) in cash and cash equivalents 173,384 (42,501) Cash and cash equivalents at the beginning of period 60,122 75,963 ------ ------ Cash and cash equivalents at the end of period $233,506 $33,462 ======== =======

    Contact:

    Michael Watts
    Vice president, investor relations and
    corporate communications
    858-410-8673

'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Reports Financial Results for First Quarter 2009
3. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
4. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
5. Tepnel Shareholders Approve Acquisition by Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
7. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
8. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
9. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
10. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
11. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference